| Identification | Back Directory | [Name]
NMS-P118 | [CAS]
1262417-51-5 | [Synonyms]
CS-2354
NMS-P118
NMS-P118; NMS-P 118; NMS P118
2-(1-(4,4-difluorocyclohexyl)piperidin-4-yl)-6-fluoro-3-oxoisoindoline-4-carboxamide
2-[1-(4,4-Difluorocyclohexyl)-4-piperidinyl]-6-fluoro-2,3-dihydro-3-oxo-1H-isoindole-4-carboxamide
2-[1-(4,4-difluorocyclohexyl)-piperidin-4-yl]-6-fluoro-3-oxo-2,3-dihydro-1H-isoindole-4-carboxamide
1H-Isoindole-4-carboxamide, 2-[1-(4,4-difluorocyclohexyl)-4-piperidinyl]-6-fluoro-2,3-dihydro-3-oxo- | [Molecular Formula]
C20H24F3N3O2 | [MDL Number]
MFCD30533610 | [MOL File]
1262417-51-5.mol | [Molecular Weight]
395.42 |
| Chemical Properties | Back Directory | [storage temp. ]
Store at -20°C | [solubility ]
DMF: 5 mg/ml; DMSO: 2 mg/ml; Ethanol: slightly soluble | [form ]
A crystalline solid | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
2-[1-(4,4-Difluorocyclohexyl)-4-piperidinyl]-6-fluoro-2,3-dihydro-3-oxo-1H-isoindole-4-carboxamide is a nuclear protein poly(ADP-ribose) polymerase-1 (PARP-1) inhibitor. PARP-1 is involved with the signaling and repair of DNA and a target in oncology. | [in vivo]
NMS-P118 is a potent (KD=0.009 μM) PARP-1 inhibitor, showing 150-fold selectivity over PARP-2 (KD=1.39 μM). NMS-P118 possesses excellent pharmacokinetic profile and nearly complete oral bioavailability both in mice and rats. It proved to be highly efficacious in vivo both as single agent in MDA-MB-436 human breast cancer tumors and in combination with temozolomide in CAPAN-1 human pancreatic tumors growing as xenografts in the mouse. The compound is well tolerated at highly efficacious doses and is endowed with an excellent ADME profile[1]. | [IC 50]
PARP-1: 9 nM (Kd); PARP-2: 1390 nM (Kd) |
|
|